Darbepoetin Alfa
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Darbepoetin Alfa: From Chronic Kidney Disease Anaemia to Amenorrhea
One-Sentence Summary
Darbepoetin alfa is a long-acting erythropoiesis-stimulating agent (ESA), widely used internationally to treat anaemia associated with chronic kidney disease and chemotherapy, though it holds no current registration in Singapore. The TxGNN model predicts it may be effective for Amenorrhea, yet this is currently supported by no clinical trials and no publications. Given the highly speculative mechanistic link and complete absence of supporting evidence, this prediction warrants a firm Hold at this stage.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Anaemia associated with chronic kidney disease; chemotherapy-induced anaemia |
| Predicted New Indication | Amenorrhea |
| TxGNN Prediction Score | 96.73% |
| Evidence Level | L5 |
| Singapore Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available from DrugBank. Based on known pharmacology, darbepoetin alfa is a hyperglycosylated analogue of recombinant human erythropoietin (EPO). It binds to and activates the erythropoietin receptor (EPOR) on erythroid progenitor cells in the bone marrow, stimulating differentiation and proliferation of red blood cells. Its modified glycosylation profile extends its half-life relative to standard epoetin, allowing less frequent dosing.
The theoretical rationale for amenorrhea rests on a distant biological observation: EPOR has been detected in low levels in reproductive axis tissues, including endometrial cells and ovarian granulosa cells. It has been proposed that EPO signalling may exert minor modulatory effects on the hypothalamic-pituitary-gonadal (HPG) axis. However, this connection is extremely indirect — amenorrhea arises from complex hormonal dysregulation (e.g., hypothalamic suppression, hyperprolactinaemia, ovarian failure) that lies well outside darbepoetin alfa's established mechanism.
The original therapeutic area (bone marrow erythropoiesis in CKD and chemotherapy patients) shares no meaningful overlap with the reproductive endocrinology of amenorrhea. The high TxGNN score (96.73%) most likely reflects a shared receptor expression node in the knowledge graph rather than a clinically actionable biological pathway. This prediction should be treated as hypothesis-generating at best.
Clinical Trial Evidence
Currently no related clinical trials registered for Darbepoetin alfa in amenorrhea.
Literature Evidence
Currently no related literature available for Darbepoetin alfa in amenorrhea.
Singapore Market Information
Darbepoetin alfa holds no active product licences in Singapore. The drug is not currently marketed or registered with HSA. Any future development or importation would require a full regulatory filing from scratch.
Safety Considerations
Please refer to the package insert for safety information.
Note: Safety data (including key warnings, contraindications, and drug interactions) was not retrievable during this assessment. Of particular importance for future review: the U.S. FDA has issued a Black Box Warning for ESAs (including darbepoetin alfa) regarding increased risk of death, serious cardiovascular events, thromboembolic events, and tumour progression in certain patient populations. These warnings must be obtained from the official product labelling before any further evaluation proceeds.
Conclusion and Next Steps
Decision: Hold
Rationale: The top predicted indication (amenorrhea) achieves Evidence Level L5 — model prediction only — with zero supporting clinical trials or published literature. The proposed mechanistic link via EPOR expression in reproductive tissues is highly speculative, and no preclinical or clinical work has validated this hypothesis. Furthermore, the drug carries known serious safety risks (cardiovascular, thrombotic, and oncologic) that have not yet been formally assessed in this context.
To proceed, the following is needed:
- Retrieve full mechanism of action data from DrugBank (DB00012) to formally characterise EPO receptor biology in reproductive tissues
- Obtain the official product package insert to document Black Box Warnings, contraindications, and key drug interactions — currently a blocking data gap
- Commission a targeted literature search for EPO/EPOR and reproductive axis biology (preclinical models) to determine whether the hypothesis merits any further investigation
- Conduct a benefit-risk scoping review: given that darbepoetin alfa has known allergic/anaphylactic potential and serious systemic risks, any new indication study would require robust safety monitoring design
- Confirm Singapore regulatory pathway requirements (HSA), as the drug has no existing local registration, adding significant regulatory lead time to any development programme
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.